GY48LS6

Кеймбридж
[ ]
Вакцина BNT162
Международное непатентованное наименование Вакцина BNT162
Торговое наименование -
Производитель, страна Biontech RNA Pharmaceuticals, Germany & Pfizer, USA
Механизм действия

mRNA-based vaccine targeting infectious disease pathogens.

Опыт использования

The four vaccine candidates to be studied each represent different mRNA formats and target antigens. Two of the four vaccine candidates include a nucleoside modified mRNA (modRNA), one includes a uridine containing mRNA (uRNA) and the fourth vaccine candidate utilises self-amplifying mRNA (saRNA).

 

Each mRNA format is combined with a lipid nanoparticle (LNP) formulation. The larger Spike sequence is included in two of the vaccine candidates and the smaller optimised receptor binding domain (RBD) from the Spike protein is included in the other two candidates.

 

The RBD-based candidates contain the piece of the spike that is thought to be most important for eliciting antibodies that can inactivate the virus.

Публикации COVID-19

Venkatesh Pooladanda, Sowjanya Thatikonda, Chandraiah Godugu. The current understanding and potential therapeutic options to combat COVID-19. Life Sciences. 8 May 2020, 117765. DOI: 10.1016/j.lfs.2020.117765.

Клинические исследования
1.
Название протокола A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS
Дата начала и окончания КИ April 29, 2020 - January 27, 2023
Название организации, проводящей КИ Biontech SE
Страны USA
Фаза I-II
Кол-во пациентов 7600
2.
Название протокола A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy Adults
Дата начала и окончания КИ April 23, 2020 - August 2020
Название организации, проводящей КИ Biontech RNA Pharmaceuticals GmbH
Страны Germany
Фаза I-II
Кол-во пациентов 200